GLYCIPHAGE PG® Tablets
Composition:
GLYCIPHAGE-PG1®
Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P. ……. 500 mg (in sustained-release form)
- Pioglitazone Hydrochloride I.P. equivalent to
Pioglitazone…………………… 15 mg - Glimepiride I.P. ……………. 1 mg
- Excipients …………….………… q.s.
- Colour: Lake of Erythrosine (C.I. No 45430)
GLYCIPHAGE-P2®
Each uncoated bilayered tablet contains:
- Metformin Hydrochloride I.P …. 500 mg (in sustained-release form)
- Pioglitazone Hydrochloride I.P. equivalent to Pioglitazone………...15 mg
- Glimepiride I.P. ……….…… 2 mg
- Excipients ….……………….….. q.s.
- Colour: Lake of Quinoline Yellow (C.I. No. 47005)
Description
- GLYCIPHAGE-PG contains three oral anti-hyperglycaemic drugs, Metformin Sustained-release, Pioglitazone hydrochloride and Glimepiride used in the management of Type 2 Diabetes.
- Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity further increasing peripheral glucose uptake and utilization.
- Pioglitazone is an agonist for peroxisome proliferator- activated receptor-gamma (PPAR- γ). Pioglitazone decreases hepatic glucose output, increases glucose utilization by skeletal muscles and increases lipogenesis in adipose tissues and adipogenesis.
- The primary mechanism of action of Glimepiride in lowering blood glucose appears to be dependent on stimulating the production and release of insulin from functioning pancreatic beta cells.
- Hence, the combination of Metformin sustained-release, Pioglitazone and Glimepiride complement each other and provide better glycaemic control in the management of Type 2 Diabetes and probably helps in the prevention of diabetes-associated macrovascular and microvascular complications.
Indications
- GLYCIPHAGE-PG® is indicated as second-line therapy when diet, exercise and dual combination therapy do not result in adequate glycaemic control in patients with type 2 diabetes.